Hrs-3005

Phase 1

JJiangsu HengRui Medicine Co., Ltd.

Hrs-3005 is one of 9 therapeutic programs targeting B-cell Malignancy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

B-Cell MalignancyRecruiting

B-Cell MalignancyPhase 1

Recruiting

Competition

Competitive Landscape

9 competitors in B-Cell Malignancy

#DrugCompanyPhaseTrials

LUNSUMIO

Roche

Preclinical

1 2

COLUMVI

Roche

Preclinical

1 3

Gazyva

Roche

Preclinical

1 4

Beqalzi

BBeOne Medicines

Preclinical

1 5

Brukinsa

BBeOne Medicines

Preclinical

1 6

BGB-16673

BBeOne Medicines

Preclinical

3 7

Hrs-3005

JJiangsu HengRui Medicine Co., Ltd.

Phase 1

1 8

Tacabrutideg

MMassachusetts General Hospital

Preclinical

2 9

Anti-CD19-CAR Vector-Transduced T Cells

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

B-Cell Malignancy

NCT07556822

Clinical

Trials by Indication[1]

B-cell Malignancy1 trial

An Open-Label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-3005 in Patients With B-cell Malignancies

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT07556822·190 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hrs-3005. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Hrs-3005. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Jiangsu HengRui Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: JJiangsu HengRui Medicine Co., Ltd.

Hrs-3005

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

B-cell Malignancy1 trial

References

Drug Info

Quick Facts

Related News